Author: Maschmeyer, Georg; Donnelly, J. Peter
Title: How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation Cord-id: 50z2kdaj Document date: 2016_1_5
ID: 50z2kdaj
Snippet: Pulmonary complications affect up to 40% of patients with severe neutropenia lasting for more than 10 d. As they are frequently associated with fever and elevation of Câ€reactive protein or other signs of inflammation, they are mostly handled as pneumonia. However, the differential diagnosis is broad, and a causative microbial agent remains undetected in the majority of cases. Pulmonary side effects from cytotoxic treatment or pulmonary involvement by the underlying malignancy must always be ta
Document: Pulmonary complications affect up to 40% of patients with severe neutropenia lasting for more than 10 d. As they are frequently associated with fever and elevation of Câ€reactive protein or other signs of inflammation, they are mostly handled as pneumonia. However, the differential diagnosis is broad, and a causative microbial agent remains undetected in the majority of cases. Pulmonary side effects from cytotoxic treatment or pulmonary involvement by the underlying malignancy must always be taken into account and may provide grounds for invasive diagnostic procedures in selected patients. Pneumocystis jirovecii (in patients not receiving coâ€trimoxazole as prophylaxis), multiâ€resistant gramâ€negative bacilli, mycobacteria or respiratory viruses may be involved. Highâ€risk patients may be infected by filamentous fungi, such as Aspergillus spp., but these infections are seldom proven when treatment is initiated. Microorganisms isolated from cultures of blood, bronchoalveolar lavage or respiratory secretions need careful interpretation as they may be irrelevant for determining the aetiology of pulmonary infiltrates, particularly when cultures yield coagulaseâ€negative staphylococci, enterococci or Candida species. Nonâ€culture based diagnostics for detecting Aspergillus galactomannan, betaâ€Dâ€glucan or DNA from blood, bronchoalveolar lavage or tissue samples can facilitate the diagnosis, but must always be interpreted in the context of clinical and imaging findings. Systemic antifungal treatment with mouldâ€active agents, given in combination with broadâ€spectrum antibiotics, improves clinical outcome when given preâ€emptively. Coâ€trimoxazole remains the firstâ€line treatment for Pneumocystis pneumonia, while cytomegalovirus pneumonia will respond to ganciclovir or foscarnet in most cases. The clinical outcome of acute respiratory failure can also be successful with proper intensive care, when indicated.
Search related documents:
Co phrase search for related documents- active infection and acute respiratory distress syndrome result: 1
- active infection and low copy number: 1
- acute respiratory distress syndrome and adjunctive administration: 1, 2
Co phrase search for related documents, hyperlinks ordered by date